The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms
The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms
复制标题
DOI：
10.1081/clt-120019128
复制
发表时间：
2003-01-01
期刊：
影响因子：
--
通讯作者：
Ware, J
中科院分区：
文献类型：
--
作者：
Black, J;Emsellem, H;Ware, J
羟丁酸钠（γ-羟基丁酸盐；GHB）已被证明对治疗发作性睡病有效。然而，有报道称，长期滥用非法 GHB 后会出现戒断症状，其中涉及剂量和给药频率的增加。本试验提供了一个机会来检验这样的假设：对发作性睡病患者长期每日服用羟丁酸钠治疗剂量不会导致突然停药后戒断。 55 名发作性睡病患者服用羟丁酸钠（剂量范围 3-9 克/晚）7-44 个月（平均 21 个月），被随机分为为期 2 周的双盲期：29 名患者接受安慰剂，26 名患者继续接受羟丁酸钠治疗。在为期 2 周的试验期间，接受安慰剂 (N) 的患者报告出现以下症状：焦虑 (2)、头晕 (1)、失眠 (1) 和嗜睡 (1)。虽然这些症状可能代表轻度 GHB 戒断的可能症状，但它们也与发作性睡病的复发症状高度一致。我们的结论是，在治疗范围内突然停止慢性羟丁酸钠剂量后，几乎没有证据显示戒断症状。
Sodium oxybate (gamma-hydroxybutyrate; GHB) has demonstrated efficacy for the treatment of narcolepsy. However, there are reports of withdrawal following chronic abuse of illicit GHB which involve escalating both doses and dosing frequency. The present trial afforded an opportunity to test the hypothesis that chronic daily therapeutic dosing of sodium oxybate in narcoleptics does not cause withdrawal following abrupt cessation. Fifty-five narcoleptic patients, taking sodium oxybate (dose range 3-9 gm/night) for 7-44 months (mean 21 months), were randomized into a 2-week double-blind period: 29 patients received placebo and 26 continued to receive sodium oxybate. During this 2-week trial period, the following symptoms were reported in patients receiving placebo (N): anxiety (2), dizziness (1), insomnia (1) and somnolence (1). While these symptoms may represent possible symptoms of mild GHB withdrawal, they are also highly consistent with the returning symptoms of narcolepsy. We conclude there is minimal evidence of withdrawal symptoms following abrupt cessation of chronic sodium oxybate dosing in the therapeutic range.